Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (United States) has no DMF, CEP or site registration linked in our records. 3 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Alnylam Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/alnylam-pharmaceuticals-inc
Overview
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development of RNAi therapeutics. The company focuses on genetic-driven and rare diseases with a comprehensive pipeline leveraging their RNA interference platform.
Therapeutic areas
FDA compliance signals
3 FDA enforcement records linked to this company.
- 4832025-02-25
Component written specification
- 4832025-02-25
Record maintenance 1 year (except exempt OTC)
- 4832025-02-25
Quality control unit review of records
Is this Alnylam Pharmaceuticals, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.